Tous Actualités
Suivre
Abonner Epigenomics AG

Epigenomics AG

EANS-News: Epigenomics Signs Distribution Deal with DATEKS for Epi proColon in Turkey

BERLIN and SEATTLE, October 28, 2010 (euro adhoc) -

Second distributor to be signed-up for Epi proColon - more expected 
to come shortly
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information/Molecular diagnostics
Subtitle: Second distributor to be signed-up for Epi proColon - more 
expected to come shortly
Epigenomics AG
(Frankfurt Prime Standard: ECX), the cancer diagnostics company, 
today announced that they have signed an exclusive distributor 
agreement with Turkish DATEKS Company Ltd for the commercialization 
of Epigenomics' Epi proColon test in Turkey.
Epi proColon is the world's first CE-marked molecular diagnostic test
for the early detection of colorectal cancer in blood. The test uses 
Epigenomics' proprietary colorectal cancer biomarker Septin9 in blood
plasma. DATEKS expects to begin marketing the test in Turkey in the 
next few weeks.
Cancer is a major threat to public health in Turkey. It is the second
biggest cause of death in the country preceded only by cardiovascular
disease. Despite the establishment of Cancer Early Diagnosis and 
Screening Centers (KETEM) in most provinces and the introduction of 
colorectal cancer screening standards by the Turkish Ministry of 
Health in 2009, screening participation is still low. Current 
screening guidelines propose stool testing at two year intervals and 
colonoscopy every ten years for men and women aged between 50 and 70 
but very few people make use of these options. This has severe 
consequences as colorectal cancer is highly curable when detected at 
an early still localized stage. Survival chances, however, diminish 
once the tumor has spread to distant organs and the disease has 
become obvious with patients showing symptoms.
"Epi proColon facilitates the early detection of colorectal cancer, 
making screening easier and more patient-friendly than ever," Süha 
Dere, Chief Executive Officer of DATEKS explained. "As a blood test, 
it is a simple and clean solution for the patients. Importantly, it 
can be performed at any time as it does not require any preparation 
of the screened individual. We believe that this test can help 
significantly to drive acceptance of colorectal cancer early 
detection in the Turkish population."
"With DATEKS we have found a very committed exclusive distributor for
the Turkish market," commented Geert Nygaard, Chief Executive Officer
of Epigenomics. "Going forward DATEKS will be an important partner in
our continuously growing distributor network for our Epi proColon 
product"
Epi proColon is currently marketed by Epigenomics directly in 
Germany, Austria and Switzerland. Outside this home market, it is 
Epigenomics' strategy to make the CE-marked test broadly available 
through a mix of direct commercialization and a distributor network.
Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368 
pr@epigenomics.com
www.epigenomics.com
About Epigenomics
Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation 
biomarkers, Epigenomics' tests on the market and in development for 
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases thereby potentially 
increasing the patient's chances of survival.
For development and global commercialization of IVD test products, 
Epigenomics pursues a dual business strategy in which direct 
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with 
broad customer access. Strategic diagnostics industry partners 
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics 
Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc. 
for diagnostics test products and services, and QIAGEN N.V. for 
sample preparation solutions and research products.
The company is headquartered in Berlin, Germany, and has a wholly 
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more 
information, please visit Epigenomics' website at www.epigenomics.com
About DATEKS
DATEKS LTD. (www.dateks.com) is a pioneer in the distribution of 
products for cell culture, molecular biology, and genetics in Turkey.
DATEKS successfully represents, among others, companies like Greiner 
Bio-One, Biochrom, AppliChem, and Machery-Nagel some of which 
distribute their products in Turkey through DATEKS for more than 20 
years. While the focus initially was on products for the research 
market, DATEKS since 2009 increasingly serves the diagnostics market.
The company is headquartered in Ankara with branch offices in 
Istanbul, Izmir, and Antalya.
Notes for editors
Epi proColon
Epi proColon, developed by Epigenomics, is a CE-marked test kit for 
the detection of methylated DNA of the Septin9 gene in blood plasma. 
This Septin9 biomarker has been shown in numerous clinical studies to
be closely associated with the presence of colorectal cancer and may 
aid in the detection of this common cancer. Septin9 is one of the 
best and most systematically validated biomarkers for the early 
detection of colorectal cancer today. In particular, the recent 
PRESEPT Study was a successful prospective evaluation of Epi proColon
detection of methylated Septin9 in a cohort of about 8,000 
individuals representative of a typical screening population.
Epigenomics' legal disclaimers. This communication expressly or 
implicitly contains certain forward-looking statements concerning 
Epigenomics AG and its business. Such statements involve certain 
known and unknown risks, uncertainties and other factors which could 
cause the actual results, financial condition, performance or 
achievements of Epigenomics AG to be materially different from any 
future results, performance or achievements expressed or implied by 
such forward-looking statements. Epigenomics AG is providing this 
communication as of this date and does not undertake to update any 
forward-looking statements contained herein as a result of new 
information, future events or otherwise.
The information contained in this communication does not constitute 
nor imply an offer to sell or transfer any product, and no product 
based on this technology is currently available for sale by 
Epigenomics in the United States of America. The analytical and 
clinical performance characteristics of any product based on this 
technology which may be sold at some future time in the USA have not 
been established.
end of announcement                               euro adhoc

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Plus de actualités: Epigenomics AG
Plus de actualités: Epigenomics AG